Last reviewed · How we verify
NCT04539106
Intravitreal Ranibizumab in Recurrent ROP
trial testing intravitreal injection of Ranibizumab in Retinopathy of Prematurity in 115 participants. Completed in 1 February 2020.
1 February 2020
Quick facts
| Lead sponsor | Ameera Gamal Abdelhameed |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 115 |
| Start date | 1 June 2019 |
| Primary completion | 1 February 2020 |
| Estimated completion | 1 February 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- intravitreal injection of Ranibizumab — full drug profile →
Conditions studied
- Retinopathy of Prematurity — all drugs for Retinopathy of Prematurity →
Sponsor
Ameera Gamal Abdelhameed — full company profile →
Who can join
Eligibility, any sex, with Retinopathy of Prematurity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective study included reviewing of medical records of preterm babies who were admitted in neonatal intensive care unit (NICU) of Mansoura University children hospital (MUCH) or referred from nearby hospitals for ROP screening during the period from March 2013 to February 2020.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
Bassiouny RM, Gaafar WM, El Nokrashy A, Abdelhameed AG, et al · · 2022 · cited 6× · PMID 34711941 · DOI 10.1038/s41433-021-01814-5
Verify or expand the search:
- PubMed search for NCT04539106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of intravitreal injection of Ranibizumab
Trials testing the same drug.
- NCT05282420 — Ranibizumab Versus Aflibercept for CRVO in Young Patients. · Phase 4 · unknown
Other recruiting trials for Retinopathy of Prematurity
Currently open trials in the same condition.
- NCT05558059 — Imaging Retinal Vasculature in Infant Eyes · recruiting
- NCT06672913 — Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study · NA · recruiting
- NCT06109285 — Validation of i-ROP DL to Detect More Than Mild ROP · NA · active not recruiting
- NCT06315556 — An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Pret · recruiting
- NCT06265363 — Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey. · recruiting
Other Ameera Gamal Abdelhameed trials
Trials by the same sponsor.
- NCT04537065 — Long Term Outcome of Intravitreal Ranibizumab for ROP · completed
- NCT04430647 — Phaco-UCP Versus Phaco Alone for OAG and Cataract · NA · completed
- NCT04433936 — Corneal Tomographic Parameters in TGD · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04539106 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ameera Gamal Abdelhameed
- Last refreshed: 4 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04539106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing